Zachary J. Zimmermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zachary J. Zimmermann has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- David V. Gauvin
Department of Neurobehavioral Sciences, Charles River Laboratories – MWN, Mattawan, MI, USA
3 shared publications - David V. Gauvin
MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA
3 shared publications Alan Poling
Department of Psychology, Western Michigan University, Kalamazoo, MI, USA
2 shared publicationsDavid V Gauvin
Neurobehavioral Sciences Department, MPI Research, Mattawan, MI, USA
2 shared publications- Theodore J. Baird
MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA
2 shared publications - Alan Poling
Department of Psychology, Western Michigan University, Kalamazoo, USA
1 shared publication
Latest Publications
- 20 June 2019
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 38 (4) , 265-278
Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data
History has established that many drugs, such as the antibiotics, chemotherapies, and loop diuretics, are capable of inducing both nephrotoxicity and ototoxicity. The exact mechanisms by which cellular damage occurs remain to be fully elucidated. Monitoring the indices of renal function conducted in the Food and Drug Administration’s prescribed set of early investigational new drug (IND)–enabling studies may be the first signs of ototoxicity properties of the new drug candidate. In developing improved and efficacious new molecular entities, it is critically necessary to understand the cellular and molecular mechanisms underlying the potential ototoxic effects as early in the drug development program as possible. Elucidation of these mechanisms will facilitate the development of safe and effective clinical approaches for the prevention and amelioration of drug-induced ototoxicity prior to the first dose in man. Biomarkers for nephrotoxicity in early tier I or tier II nonclinical IND-enabling studies should raise an inquiry as to the need to conduct a full auditory function assay early in the game to clear the pipeline with a safer candidate that has a higher probability of continued therapeutic compliance once approved for distribution.
- 20 June 2019
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 38 (4) , 265-278
Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data
History has established that many drugs, such as the antibiotics, chemotherapies, and loop diuretics, are capable of inducing both nephrotoxicity and ototoxicity. The exact mechanisms by which cellular damage occurs remain to be fully elucidated. Monitoring the indices of renal function conducted in the Food and Drug Administration’s prescribed set of early investigational new drug (IND)–enabling studies may be the first signs of ototoxicity properties of the new drug candidate. In developing improved and efficacious new molecular entities, it is critically necessary to understand the cellular and molecular mechanisms underlying the potential ototoxic effects as early in the drug development program as possible. Elucidation of these mechanisms will facilitate the development of safe and effective clinical approaches for the prevention and amelioration of drug-induced ototoxicity prior to the first dose in man. Biomarkers for nephrotoxicity in early tier I or tier II nonclinical IND-enabling studies should raise an inquiry as to the need to conduct a full auditory function assay early in the game to clear the pipeline with a safer candidate that has a higher probability of continued therapeutic compliance once approved for distribution.
- 19 June 2018
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 32 (8) , 900-910
Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley rats
Background: Levamisole (LVM) is a common adulterant in clandestinely manufactured cocaine (COC), with a range of well-documented deleterious health effects. Although the prevalence of LVM in COC has been widely noted, the subjective effects related to concomitant COC-LVM administration are poorly understood.Aims: The present study sought to compare the subjective effects of LVM alone and in combination with COC in male and female Sprague-Dawley rats trained to discriminate COC from vehicle injections.Methods: Male and female Sprague-Dawley rats were trained to discriminate COC from vehicle injections using a two-lever, food-reinforced drug discrimination procedure. Subsequent dose-effect curves were generated for COC, LVM, and a variety of COC-LVM combinations.Results: No significant difference in males and females was observed on any measure of responding. LVM alone dose-dependently decreased response rates and failed to produce substitution for COC. When LVM was administered with COC, previously ineffective doses of COC engendered COC-appropriate responding.Conclusions: LVM potentiates the subjective effects of COC when administered concomitantly. These findings are consistent with the popular notion that LVM is added as an adulterant to COC to amplify the subjective effects of COC administration.
- 19 June 2018
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 32 (8) , 900-910
Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley rats
Background: Levamisole (LVM) is a common adulterant in clandestinely manufactured cocaine (COC), with a range of well-documented deleterious health effects. Although the prevalence of LVM in COC has been widely noted, the subjective effects related to concomitant COC-LVM administration are poorly understood.Aims: The present study sought to compare the subjective effects of LVM alone and in combination with COC in male and female Sprague-Dawley rats trained to discriminate COC from vehicle injections.Methods: Male and female Sprague-Dawley rats were trained to discriminate COC from vehicle injections using a two-lever, food-reinforced drug discrimination procedure. Subsequent dose-effect curves were generated for COC, LVM, and a variety of COC-LVM combinations.Results: No significant difference in males and females was observed on any measure of responding. LVM alone dose-dependently decreased response rates and failed to produce substitution for COC. When LVM was administered with COC, previously ineffective doses of COC engendered COC-appropriate responding.Conclusions: LVM potentiates the subjective effects of COC when administered concomitantly. These findings are consistent with the popular notion that LVM is added as an adulterant to COC to amplify the subjective effects of COC administration.
- 1 November 2017
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 88, 123-129
Down for the count: The critical endpoint in ototoxicity remains the cytocochleogram
- 1 November 2017
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 88, 123-129
Down for the count: The critical endpoint in ototoxicity remains the cytocochleogram
- 16 October 2017
- Published by Springer Nature in The Psychological Record
- Vol. 67 (4) , 559-567
Effects of Levamisole on Cocaine Self-Administration by Rats
- 16 October 2017
- Published by Springer Nature in The Psychological Record
- Vol. 67 (4) , 559-567
Effects of Levamisole on Cocaine Self-Administration by Rats
- 1 November 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 168, 307-319
Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?
- 1 November 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 168, 307-319
Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?
- Open Access
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Journal of Drug Abuse
- Vol. 2 (1)
The Lexicon of Drug Abuse
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Journal of Drug Abuse
- Vol. 2 (1)
Open AccessThe Lexicon of Drug Abuse
- 1 October 2015
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 73 (1) , 43-54
Preclinical assessment of abuse liability of biologics: In defense of current regulatory control policies
- 1 October 2015
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 73 (1) , 43-54
Preclinical assessment of abuse liability of biologics: In defense of current regulatory control policies
- 30 August 2014
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 125, 65-69
Increasing food deprivation relative to baseline influences d -amphetamine dose–response gradients
- 30 August 2014
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 125, 65-69
Increasing food deprivation relative to baseline influences d -amphetamine dose–response gradients